# Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

> **NCT00551265** · NA · WITHDRAWN · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Recurrent Ovarian Carcinoma
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Oregovomab

## Key facts

- **NCT ID:** NCT00551265
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-10
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551265, "Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00551265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*